An observational study in Migraine, Migraine With Aura and Migraine Without Aura, sponsored by Austrian Migraine Registry Collaboration. Recruiting at 3 sites in Austria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-10-20.
Sponsored by Austrian Migraine Registry Collaboration · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Migraine Disorders with a site in Austria — 4 open to participants now, 6 under way, 2 of them phase 3. Migraine Disorders · Austria.
Among the 20 studies in Migraine Disorders with a site in Austria, this one is one of 4 that started in 2022, is one of 3 observational ones, and was the 10th registered.
1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →4 of the 20 studies in Migraine Disorders with a site in Austria are open now. Recruiting first, the newest first:
Brightmind.AI · Sites in Austria
Ages 18–65
Medical University of Vienna · Sites in Austria
Ages 18–64 · Healthy volunteers
Bernhard Taxer · Sites in Austria
Ages 18–65 · Healthy volunteers
A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,500 is above the median of 138 across 332 observational studies indexed under Migraine Disorders.
Median enrollment 621 across the 17 interventional studies, 120 across the 3 observational. Of the 14 that completed or were terminated, 10 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 20 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Austrian Migraine Registry Collaboration as lead sponsor.
Austrian Migraine Registry Collaboration has 1 study filed under Migraine Disorders — fewer than ten, so there is no comparison to draw.
2 of the studies in Migraine Disorders with a site in Austria that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07018700Phase 3Merz Therapeutics GmbHA Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine | 2027-03 |
| NCT07018713Phase 3Merz Therapeutics GmbHA Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine | 2027-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 20 studies in Migraine Disorders with a site in Austria, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The present non-interventional study on migraine prevention with monoclonal CGRP antibodies adresses questions concering safety, swichting from one CGRP mab to another, efficacy on auras in the real world setting.
Introduction:
Monoclonal antibodies against calcitonin gene-related peptide (CGRP) or its receptor (CGRP-R) are an effective option for the preventative treatment in episodic and chronic migraine. All monoclonal antibodies against CGRP or CGRP-R have been proven efficacious in all various treatment endpoints (i.e. reduction of MMDs, improvement in Quality of Life etc.) in randomized phase 3 trials and were therefore approved by FDA and EMA. However, real world clinical experience/data in "non-study" patients is lacking as is data on long-term efficacy, elderly or data on switchers between antibodies that cannot be derived out of previous trials.
Phase 3 and 4 studies have addressed issues of efficacy and safety in highly selected clinical study populations and so far no safety concerns have emerged. However, long-term data are limited to a maximum period of 5 years and have been acquired in selected study cohorts probably not reflecting a "real world" patient population. It is a main goal of the study to acquire data on safety and efficacy in a real world setting where patients will be less selected than in clinical studies in terms of accompanying diseases or comorbidities. Another knowledge gap concerns the optimal procedure when switching the patient from one anti-CGRP therapy to another or being paused (and re-initiated) after a first successful treatment period. With specific evidence lacking, it is frequently recommended to wait several half-lives before initiating the next anti-CGRP therapy. Another unresolved question is whether non-responders to CGRP ligand blockers may respond to CGRP-receptor blockers and vice versa. While efficacy of anti-CGRP therapies has been demonstrated for migraine with and without aura, possible effects on the migraine auras per se have not been reported.
Phase 4 studies (non-interventional studies) on treatment with anti-CGRP therapies are being conducted in several countries in Europe. These are, however, limited to one specific substance. The proposed project will allow collecting data on the use of erenumab, fremanezumab, and galcanezumab on a nation- wide basis up to 36 months in a real-life setting.
The following knowledge should emerge from the registry:
Anti-CGRP therapies can be safely used in a wide spectrum of migraine patients with comorbidities and accompanying diseases over a long time period. There will be evidence how patients can be switched from one CGRP antibody to another. There will be an evidence base to switch anti-CGRP-therapies from ligand- to receptor- blockers or vice versa. Additionally the question whether a mAB even if effective should be paused or not after 1 year of treatment and what effect this pause might have will be addressed subsequently.
Methods Collected data will be entered in an electronic platform provided by Health Austria (https://goeg.at/) which has long-term experience in conducting and maintaining nation-wide registries, e.g. the Austrian Stroke Registry.
Non interventional study - The decision for therapy with an anti-CGRP monoclonal antibody/ CGRP antagonist is made by the treating physician and is NOT part of the Study. The study was approved by the relevant ethics committees and registered at a platform of the Austrian Agency for Health an Nutrition Safety at https://forms.ages.at/nis/. All patients treated in the headache centers are keeping headache diaries on paper or in electronic form as a standard of care procedure. Prospective and retrospective data collection from electronic charts is possible. Data are collected during routine visits which are scheduled in 3 months intervals. Collected data will be entered in an electronic platform provided by Health Austria (https://goeg.at/) in an anonymized form.
Study funding: Scientific reports concerning fremanezumab will be provideded to TEVA Austria, reports on erenumab to Novartis Austria and on galcanezumab to Eli Lilly Austria, based on financial compensation agreements.
Male or female adult patients of at least 18 years or older in whom CGRP mabs can be prescribed according to Austrian regulations. These include treatment failure or intolerability / contraindications of at least 3 prophylactic medications. Documentation of treatment in a headache diary on paper or in digital format.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients will be treated with this drug within standard of care treatment
Drug: Erenumab
Patients will be treated with this drug within standard of care treatment
Drug: Galcanezumab
Patients will be treated with this drug within standard of care treatment
Drug: Fremanezumab
treatment with erenumab as chosen by treating physician
treatment with fremanezumab as chosen by treating physician
treatment with galcanezumab as chosen by treating physician
Change in Migraine days per month (= 4 weeks) from baseline to month 6
Either of the following: (i) patient has treated headache with a triptan (ii) criteria C+ D for migraine without aura are fulfilled (iii) criteria B+C for migraine with aura are fulfilled
Time frame: 6 months
Change in headache days per month (= 4 weeks) from baseline to month 6
Any day with headache
Time frame: 6 months
Change in aura days per month (= 4 weeks) from baseline to month 6
Any day with at least one migraine aura
Time frame: 6 months
Change in days with acute headache medication per month (= 4 weeks) from baseline to month 6
Any days on which medication against migraine was taken by the patient
Time frame: 6 months
Change in days with triptans per month (= 4 weeks) from baseline to month 6
Any days on which triptans medication were taken by the patient
Time frame: 6 months
Change in headache intensity from baseline to month 6
Usual intensity of headche attacks on a numerical rating scale from 1 -10. Higher numbers indicate more severe headache attacks
Time frame: 6 months
Change in unpleasantness of aura from baseline to month 6
Usual unpleasantness of aura on a numerical rating scale from 1 -10. Higher numbers indicate more unpleasantness.
Time frame: 6 months
Change in migraine duration from baseline to month 6
Usual duration of migraine headache attack
Time frame: 6 months
Change in migraine aura duration from baseline to month 6
Usual duration of migraine aura
Time frame: 6 months
Subjective change in quality of life from baseline to month 6
3 point scale: improved, unchanged, worse
Time frame: 6 months
Change in MIDAS (Migraine Diasability Assessment Questionnaire) scores from baseline to month 6
Migraine Disability Assessment Questionnaire. A higher Score indicates more disability. mnimum = 0, maximum =270
Time frame: 6 months
Change in impact of headache from baseline to month 6
Questionnaire. Higher scores indicate more impact of headache. Minmum= 36, maximum =38
Time frame: 6 months
Adverse events
Any treatment emergent adverse events, Causality according to FDA rating: unlikely, possible, probable
Time frame: Up to 36 months. Assessment every 3 months, may differ between study centers.
Serious adverse events
Definiation and causality according to FDA
Time frame: Up to 36 months. Assessment every 3 months, may differ between study centers. Baseline refers to the 4 weeks interval before treatment start
Started Oct 2022 (actual). Primary completion is estimated for Sep 2025, 35 months after the start.
Of 132 non-industry observational studies under Migraine Disorders, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 72. This study's planned 35 months is above that.
Counting every sponsor, half of 160 studies reached it within 27 months; a quarter within 12 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.